The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline

Muhamad Frendy Setyawan, Ni Made Mertaniasih, Soedarsono Soedarsono


Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the  MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July  2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)%  respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.


drug-resistant tuberculosis; treatment regimen; bedaquiline; WHO guidelines; pulmonary tuberculosis


Oliveira O, Gaio R, Correia-Neves M, Rito T, Duarte R. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000–2016. PLoS One. 2021;16(4 April).

Khan I, Ahmad N, Khan S, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019;12(6):809–15.

Secretary of Jan Swasthya Sahyog, Laux TS, Patil S. Predictors of tuberculosis treatment outcomes among a retrospective cohort in rural, Central India. J Clin Tuberc Other Mycobact Dis. 2018;12:41–7.

El-Shabrawy M, El-Shafei DA. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(1):145–52.

Guglielmetti L, Hewison C, Avaliani Z, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. International Journal of Tuberculosis and Lung Disease. 2017;21(2):167–74.

Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.

Gao JT, Shu W, Zhang LJ, et al. Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports. World J Clin Cases. 2021;9(10):2326–33.

Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clinical Microbiology and Infection. 2021;27(4):597–602.

Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):E93–142.

MR, Padayatchi N, Wolf A, et al. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/ AIDS [Internet]. Vol. 90, J Acquir Immune Defic Syndr. 2022. Available from:|325

Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403–12.

Fekadu G, Yao J, You JHS. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis. PLoS One. 2022;17(8 August).

Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: Current status and future perspectives. Journal of Global Antimicrobial Resistance. Elsevier Ltd; 2021;25:48–59.

Mirzayev F, Viney K, Linh NN, et al. World health organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal. 2021;57.

Putra ON, Damayanti A, Wijayanti N, Nurrahman D, Devi T, Aluf W. Evaluation of category I of anti-tuberculosis therapy in intensive phase pulmonary TB by conversion of acid-fast Bacilli sputum. Original Article Pharmaceutical Sciences and Research (PSR). 2019;6(3):183–8.

Pontali E, Raviglione MC, Migliori GB, et al. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. European Respiratory Review. 2019;28.

WHO. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis [Internet]. 2022. Available from:

Indarti HT, Kristin E, Soedarsono S, Endarti D. Treatment outcomes of multidrug-resistant Tuberculosis patients in East Java, Indonesia: A retrospective cohort analysis. Int J Mycobacteriol. 2022;11(3):261–7.

Giri VP, Giri OP, Pandey PT, et al. The Characteristics and patterns of Drug-Resistant Pulmonary Tuberculosis in Eastern India. Trop Med Infect Dis. 2022;7(9).

Pai H, Ndjeka N, Mbuagbaw L, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect Dis. 2022;22(1).

Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1).

Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid, and Clofazimine for treatment of pre-extensively drug-resistant Tuberculosis. Clinical Infectious Diseases. 2023;76(3):E938–46.

Hewison C, Khan U, Bastard M, et al. Safety of treatment regimens containing Bedaquiline and Delamanid in the end TB cohort. Clinical Infectious Diseases. 2022;75(6):1006–13.

Kim JH, Lee H, Oh IS, et al. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study. Journal of Microbiology, Immunology and Infection. 2023;56(4):842–52.

Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1).

Traoré AN, Rikhotso MC, Banda NT, et al. Effectiveness of the novel anti-TB Bedaquiline against drug-resistant TB in Africa: A systematic review of the literature. Pathogens. MDP. 2022;11.

Fu L, Weng T, Sun F, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. International Journal of Infectious Diseases. 2021;111:138–47.

World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4, Treatment: drug-resistant tuberculosis treatment. [Internet]. 2020 [cited 2022 Oct 22]. 98 p. Available from:

Nunn AJ, Rusen ID, van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial. Trials. 2014;15(1).

Borisov SE, D’Ambrosio L, Centis R, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection. 2019;78(1):35–9.

Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403–12.

Deshkar AT, Shirure PA. Bedaquiline: A novel diarylquinoline for multidrug-resistant pulmonary Tuberculosis. Cureus. 2022.

Belachew T, Yaheya S, Tilahun N, et al. Multidrug-resistant Tuberculosis treatment outcome and associated factors at the University of Gondar comprehensive specialized hospital: A ten-year retrospective study. Infect Drug Resist. 2022;15:2891–9.

Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study. European Respiratory Journal. 2017;49(5).

Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1).

Mase S, Chorba T, Parks S, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clinical Infectious Diseases. 2020;71(4):1010–6.

Lee T, Lee SJ, Jeon D, et al. Additional drug resistance in patients with multidrug-resistant Tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci. 2021;36(26):1–11.

Ministry of Health and Family Welfare India. Guideline for programmatic multidrug resistant TB in India 2021. Ministry of Health and Family Welfare India [Internet]. 2021 [cited 2022 Dec 16]; Available from:

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.